Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03860272 trial: what clinicians have said so far
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
- NCT03860272 ↗
- Active, not recruiting
- Agenus Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT03860272 (botensilimab plus balstilimab; botensilimab in advanced cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03860272 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Advanced Cancer; Angiosarcoma; Colorectal Cancer Without Liver Metastases; Endometrial Cancer; Fibrolamellar Carcinoma; Non-small-cell Lung Cancer; Ovarian Cancer; Prostate Cancer
- Interventions
- Botensilimab; Balstilimab
- Arms
- 3-Week Monotherapy · Experimental
- 6-Week Monotherapy · Experimental
- 6-Week Combination Therapy · Experimental
- Enrollment
- 499
- Primary outcomes
- Incidence Of Treatment-emergent Adverse Events (TEAEs)
- DLT Of Botensilimab
- RP2D Of Botensilimab
- Sponsor
- Agenus Inc.
- Start
- Mar 20, 2019
- Primary completion
- Jan 13, 2025
- Results posted
- No
- Registry record
- NCT03860272 · updated Mar 30, 2026
Publications
linked from the registry- Bengala E, Santini D, Picone V. Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care. Immunooncol Technol. 2025 Nov 28;29:101558. doi: 10.1016/j.iotech.2025.101558. eCollection 2026 Mar. PubMed 41502912
- Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J, Delepine C, Chand D, Avagyan M, Wu W, Johnson B, Grossman JE, O'Day S, Trent JC, Jones RL, Tsimberidou AM. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. J Clin Oncol. 2025 Apr 10;43(11):1358-1368. doi: 10.1200/JCO-24-02524. Epub 2025 Jan 27. PubMed 39869830
- Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS, Sanborn RE, Schwartz GK, Abou-Alfa GK, Segal NH, Bockorny B, Moser JC, Sharma S, Patel JM, Wu W, Chand D, Rosenthal K, Mednick G, Delepine C, Curiel TJ, Stebbing J, Lenz HJ, O'Day SJ, El-Khoueiry AB. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med. 2024 Sep;30(9):2558-2567. doi: 10.1038/s41591-024-03083-7. Epub 2024 Jun 13. PubMed 38871975